Phase II Randomized Study Comparing the Toxicity Profile of Gemcitabine plus Cisplatin with Gemcitabine plus Oral Etoposide in the Treatment of Advanced Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 1423-0232|68|4-6|485-492

ISSN： 0030-2414

Source： Oncology, Vol.68, Iss.4-6, 2005-08, pp. : 485-492

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Randomized Phase II Study Comparing Two Schedules of the 21-Day Regimen of Gemcitabine and Carboplatin in Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 267-270

Karger

Access to resources Recommend Favorite

Prospective randomized double‐blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO‐AB 31/05)

By  

BJU INTERNATIONAL, Vol. 113, Iss. 3, 2014-03 ,pp. : 429-436

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 82, Iss. 1, 2012-01 ,pp. : 25-29

Karger

Access to resources Recommend Favorite

Weekly Cetuximab and Gemcitabine plus Cisplatin as Salvage Therapy for Unresectable Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 32, Iss. 11, 2009-10 ,pp. : 685-686

Karger

Access to resources Recommend Favorite

The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer

By  

Reviews on Recent Clinical Trials, Vol. 8, Iss. 1, 2013-01 ,pp. : 23-28

Bentham Science Publishers

Access to resources Recommend Favorite